Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.

JAMA network open·2022
Same author

Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.

Clinical genitourinary cancer·2021
Same author

Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021.

BJU international·2021
Same author

Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019.

Drug discovery today·2020
Same author

Chemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin.

Frontiers in genetics·2020
Same author

A case of intraplacental gestational choriocarcinoma; characterised by the methylation pattern of the early placenta and an absence of driver mutations.

BMC cancer·2019

Related Experiment Video

Updated: Jun 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Malignant melanoma (non-metastatic).

Philip Savage1

  • 1Charing Cross Hospital, London, UK.

BMJ Clinical Evidence
|May 21, 2009
PubMed
Summary

This systematic review examines melanoma interventions, finding evidence on vaccines, surgery, and adjuvant therapies. It highlights the effectiveness and safety of various treatments for malignant melanoma, aiding clinical decision-making.

Area of Science:

  • Dermatology and Oncology
  • Evidence-Based Medicine

Background:

  • Malignant melanoma incidence is rising in the UK, yet mortality remains stable.
  • Survival rates for melanoma vary widely (20-95%) based on disease stage.
  • Higher risk is observed in fair-skinned populations and individuals with numerous moles.

Purpose of the Study:

  • To systematically review the evidence on interventions for malignant melanoma prevention and treatment.
  • To assess the optimal surgical margins for primary melanoma excision.
  • To evaluate the impact of lymph node dissection and sentinel lymph node biopsy.
  • To determine the effectiveness of adjuvant therapies for melanoma.

Main Methods:

  • Systematic review of 30 studies, including systematic reviews, RCTs, and observational studies.

More Related Videos

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
07:31

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Experiment Videos

Last Updated: Jun 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
07:31

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

  • Searched major databases (Medline, Embase, Cochrane Library) up to October 2006.
  • Included safety alerts from regulatory agencies (FDA, MHRA).

    • Main Results:

    • Evaluated the quality of evidence for various interventions using the GRADE system.
    • Identified studies addressing prevention, surgical margins, lymph node assessment, and adjuvant treatments.
    • Synthesized findings on the effectiveness and safety of reviewed interventions.

    Conclusions:

    • Presents data on the effectiveness and safety of adjuvant vaccines, lymph node dissection, and sentinel lymph node biopsy.
    • Reviews evidence for adjuvant interferon alfa (low, intermediate, high dose) and sunscreens.
    • Discusses surveillance for early recurrence and wide excision techniques.